| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/21/2006 | DE102005012060A1 Orales Produkt zur Vorbeugung und Behandlung von Windeldermatitis Oral product for the prevention and treatment of diaper rash |
| 09/21/2006 | DE102005011822A1 Phthalazinone Phthalazinones |
| 09/21/2006 | DE102005011517A1 Transdermales therapeutisches System zur Verabreichung von Analgetika Transdermal therapeutic system for administration of analgesics |
| 09/21/2006 | DE102004039532B4 Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel Cyclohexyl-methyloxy-substituted acetic acid derivatives, process for their preparation and their use as medicaments |
| 09/21/2006 | DE102004039509B4 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Aryl-cycloalkyl substituted alkane acid derivatives, processes for their preparation and their use as medicaments |
| 09/21/2006 | CA2759162A1 Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors |
| 09/21/2006 | CA2656966A1 A topical analgesic composition |
| 09/21/2006 | CA2656961A1 A topical anaesthetic composition |
| 09/21/2006 | CA2621943A1 Hydrocodone polymorphs |
| 09/21/2006 | CA2606329A1 Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
| 09/21/2006 | CA2602609A1 Novel anthranilic acid derivative or salt thereof |
| 09/21/2006 | CA2602098A1 Method of treating actinic keratosis |
| 09/21/2006 | CA2602089A1 Tigecycline compositions and methods of preparation |
| 09/21/2006 | CA2601897A1 Semi-synthetic taxane derivatives with antitumor activity |
| 09/21/2006 | CA2601884A1 Novel tyrosine derivatives |
| 09/21/2006 | CA2601831A1 Combination of sodium channel blockers and their derivatives with opioid antagonists |
| 09/21/2006 | CA2601717A1 Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof |
| 09/21/2006 | CA2601644A1 Fused thiazole derivatives having affinity for the histamine h3 receptor |
| 09/21/2006 | CA2601628A1 Certain substituted amides, method of making, and method of use thereof |
| 09/21/2006 | CA2601557A1 Use of 5'-methylthioadenosine (mta) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection |
| 09/21/2006 | CA2601527A1 Potassium channel modulating agents and their medical use |
| 09/21/2006 | CA2601503A1 Phenol derivatives and their use to modulate pkb activity |
| 09/21/2006 | CA2601468A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 09/21/2006 | CA2601425A1 Novel dihydropyrimidine derivatives and their use as anti-cancer agents |
| 09/21/2006 | CA2601257A1 Pyrimidine derivatives for treatment of hyperproliferative disorders |
| 09/21/2006 | CA2601250A1 Taste masked dosage form containing roflumilast |
| 09/21/2006 | CA2601179A1 Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| 09/21/2006 | CA2601137A1 The use of non-steroidal anti-inflammatory drugs by inhalation in the treatment of acute and chronic bronchitis |
| 09/21/2006 | CA2601123A1 External preparation |
| 09/21/2006 | CA2601101A1 Use of acetyl-leucine for preparing a drug for treating balance disorders |
| 09/21/2006 | CA2601051A1 Use of inhibitors of steroid (testosterone) activity (i. a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse |
| 09/21/2006 | CA2601046A1 Composition comprising isoorientin for suppressing histamine |
| 09/21/2006 | CA2601032A1 Substituted 9-alkyladenines and the use thereof |
| 09/21/2006 | CA2600985A1 1-subsituted-3,4-dihydro-pthalazin-4-ones as eg5 inhibitors |
| 09/21/2006 | CA2600904A1 Trifluoromethylbenzamide derivatives and therapeutic uses thereof |
| 09/21/2006 | CA2600868A1 Quinazolinone t-type calcium channel antagonists |
| 09/21/2006 | CA2600860A1 Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use |
| 09/21/2006 | CA2600845A1 Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| 09/21/2006 | CA2600822A1 Method for preventing cardiovascular diseases |
| 09/21/2006 | CA2600797A1 Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| 09/21/2006 | CA2600763A1 Use of 2 -anilino - 3 , 4 -dihydro - quinazolines as 5ht5a receptor antagonists |
| 09/21/2006 | CA2600761A1 Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as maob inhibitors |
| 09/21/2006 | CA2600712A1 Methods of treating cancer using ppar-gamma antagonists |
| 09/21/2006 | CA2600696A1 Synthetic anti-candida albicans oligosaccharide based vaccines |
| 09/21/2006 | CA2600681A1 Pyrimidine carboxylic acid derivatives and use thereof |
| 09/21/2006 | CA2600547A1 Benzoyl peroxide compositions and methods of use |
| 09/21/2006 | CA2600542A1 Pharmaceutical tablets of crystalline type ii aripiprazole |
| 09/21/2006 | CA2600528A1 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them |
| 09/21/2006 | CA2600521A1 N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations |
| 09/21/2006 | CA2600508A1 Arylsulfonyl benzyl ethers as 5-ht2a antagonists |
| 09/21/2006 | CA2600507A1 1,3-dihydro-benzimidazol-2-ylidene amines as inhibitors of respiratory syncytial virus replication |
| 09/21/2006 | CA2600468A1 Stabilized compositions of volatile alkylating agents and methods of using thereof |
| 09/21/2006 | CA2600399A1 Oral dosage forms of gemcitabine derivatives |
| 09/21/2006 | CA2600329A1 Combination of a steroid sulfatase inhibitor and an ascomycin |
| 09/21/2006 | CA2600301A1 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
| 09/21/2006 | CA2600038A1 2-pyridine derivatives as inhibitors of neutrophile elastase |
| 09/21/2006 | CA2600028A1 Pharmaceutical compositions containing a combination of a cannabinoid receptor antagonist compound and an antipsychotic agent |
| 09/21/2006 | CA2599925A1 Cgrp receptor antagonists |
| 09/21/2006 | CA2599901A1 Compounds for inhibiting ksp kinesin activity |
| 09/21/2006 | CA2599899A1 Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity |
| 09/21/2006 | CA2599711A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 09/21/2006 | CA2599667A1 Antimicrobial compositions comprising esters of hydroxy carboxylic acids |
| 09/21/2006 | CA2599663A1 Composition based on an avermectin and azelaic acid in particular for treating rosacea |
| 09/21/2006 | CA2599653A1 Methods of reducing microbial contamination |
| 09/21/2006 | CA2599643A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same |
| 09/21/2006 | CA2599637A1 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof |
| 09/21/2006 | CA2599575A1 A combination treatment for enhancing diuresis |
| 09/21/2006 | CA2599538A1 N-sulphonylpyrroles and their use as histone deacetylase inhibitors |
| 09/21/2006 | CA2599502A1 Sublingual coated tablet |
| 09/21/2006 | CA2599478A1 Process for the purification of duloxetine hydrochloride |
| 09/21/2006 | CA2599476A1 Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments |
| 09/21/2006 | CA2599475A1 Pure duloxetine hydrochloride |
| 09/21/2006 | CA2599473A1 Antiviral compositions and methods of use |
| 09/21/2006 | CA2599470A1 Anti-inflammatory compounds |
| 09/21/2006 | CA2599468A1 Vitamin mixtures |
| 09/21/2006 | CA2599464A1 Biocompatible polymer compounds for medicinal formulations |
| 09/21/2006 | CA2599425A1 Substituted gamma lactams as therapeutic agents |
| 09/21/2006 | CA2599391A1 Crystalline forms of ziprasidone mesylate |
| 09/21/2006 | CA2599236A1 Crystalline forms of a biphenyl compound |
| 09/21/2006 | CA2599220A1 Treatment of intestinal conditions |
| 09/21/2006 | CA2598865A1 Adenosine derivatives having a2a receptor activity |
| 09/21/2006 | CA2598695A1 Hydroxyalkyl substituted imidazoquinolines |
| 09/21/2006 | CA2598234A1 Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| 09/21/2006 | CA2597444A1 Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use |
| 09/21/2006 | CA2597349A1 Use of compounds derived from pyrimidinetrione as acetyl cholinesterase inhibitors, compositions containing said derivatives, and the uses thereof |
| 09/21/2006 | CA2597325A1 Methods and compositions for modulating vascular integrity |
| 09/21/2006 | CA2595791A1 The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| 09/21/2006 | CA2581402A1 Novel activating agent of glucose uptake and a screening method therefor |
| 09/21/2006 | CA2563533A1 Compositions capable of facilitating penetration across a biological barrier |
| 09/20/2006 | EP1702986A1 BASB013 DNA and proteins from Neisseria meningitidis |
| 09/20/2006 | EP1702985A2 Preferred segments of neural thread protein and methods of using the same |
| 09/20/2006 | EP1702984A2 A method for detecting prostate cancer |
| 09/20/2006 | EP1702983A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
| 09/20/2006 | EP1702929A2 Therapeutic use of the smr1 protein and active derivatives thereof |
| 09/20/2006 | EP1702924A2 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof |
| 09/20/2006 | EP1702921A1 Beta-lactamase-resistant cephalosporin ester compounds and salts of thereof |
| 09/20/2006 | EP1702920A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/20/2006 | EP1702919A1 Novel 2-heteroaryl-substituted benzimidazole derivative |
| 09/20/2006 | EP1702917A1 Amide derivative and medicine |
| 09/20/2006 | EP1702916A1 DPP-IV inhibitors |